Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals has initiated a Phase II study of its small-molecule thrombopoietin mimetic, LGD-4665 for the treatment of idiopathic thrombocytopenic purpura.
Subscribe to our email newsletter
The 24 patient, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura over six weeks of treatment.
John Higgins, president and CEO of Ligand, said: “We plan to initiate additional clinical studies with LGD-4665 this year. Our thrombopoietin drug program is focused on developing LGD-4665 for multiple indications as well as advancing clinically distinctive next generation molecules.”